RxNews Recap for Wednesday 12-30-09 Print E-mail
By Mary Davila   
Wednesday, 30 December 2009 18:47
Below is a list of the companies that made news in the healthcare sector on Wednesday, December 30, 2009.



Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.


Biodel, Inc. (Nasdaq: BIOD)
announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for clearance to market VIAject® as a treatment for diabetes.

Compugen Ltd. (NASDAQ: CGEN) today announced it has raised gross proceeds of $20 million, completing in full its previously announced Controlled Equity Offering facility.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has formally entered into a 50/50 joint venture, Incuron, with Bioprocess Capital Ventures, a Russian Federation venture capital fund, to develop the Company's Curaxin compounds for cancer applications.

Compugen Ltd. (NASDAQ: CGEN) today announced it has raised gross proceeds of $20 million, completing in full its previously announced Controlled Equity Offering facility.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the J.P. Morgan 28th Annual Healthcare Conference on Wednesday, Jan. 13, 2010, at 10:00 a.m. PST.David Holveck, president and chief executive officer of Endo, will review the company's products and development programs.

Entest Biomedical Inc. (OTCBB: ENTB) announced that it has filed a grant application with the National Heart, Lung and Blood Institute (NHLBI) for the development of the Company's ENT-576 Laser Device to be used in treating Chronic Obstructive Pulmonary Disease (COPD).

Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”) oday announced that it completed its Second Notes Repurchase Agreement (the “Agreement”) as of December 30, 2009 with Citadel Equity Fund Ltd. (“Citadel”) of the remaining portion of the Company’s outstanding 1% Guaranteed Senior Secured Convertible Notes due 2012 (the “Notes”) by full repayment in cash of the agreed upon purchase price due to Citadel.

Rite Aid (NYSE: RAD) now is offering the H1N1 (swine) flu shots by its certified immunizing pharmacists at 1,257 Rite Aid stores in 30 states and the District of Columbia.

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the completion of a private placement of its common stock and warrants representing an initial investment of $87,500, with an additional $87,500 should the warrants be exercised, by a group of private investors who previously purchased the Company’s stock at a 36% lower price, through a prior private placement.

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).

Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiary Warner Chilcott Corporation (the "Company") has received and accepted for purchase approximately $290.5 million aggregate principal amount of its 8-3/4% Senior Subordinated Notes due 2015 (Cusip No. 93443MAC5) (the "Notes") validly tendered by 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date"), and has received consents from holders of approximately 76% of the Notes as of the Consent Date.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter